Long‐term outcome of dietary therapy in primary intestinal lymphangiectasia: Are we achieving sustained remission? A national retrospective study

OBJECTIVES: Primary intestinal lymphangiectasia (PIL) is a rare congenital malformation causing protein-losing enteropathy. Given limited data on long-term dietary outcomes, this study describes clinical features, dietary response durability, and second-line therapies in an Italian pediatric cohort. METHODS: This multicenter retrospective study (2012-2025) analyzed children with PIL. Complete clinical remission required symptom resolution, normalized serum albumin, and intravenous albumin independence. Endoscopic and histological remissions were defined as the absence of macroscopic alterations and lymphatic vessel dilatation, respectively. RESULTS: Eighteen patients were included (median onset/diagnosis: 9 and 16 months, respectively). Key symptoms were ascites (82.4%), peripheral edema (76.5%), and lymphedema (64.7%); 94.1% showed profound hypoalbuminemia, hypoproteinemia, and hypogammaglobulinemia. Endoscopy revealed "snowflake" mucosa in 86.7%. Although all started a low-fat, high-protein medium-chain triglycerides diet, only 27.7% (5/18) achieved sustained complete remission on diet alone. Due to dietary failure, 55.6% (10/18) required second-line treatments (octreotide, sirolimus), with limited remission rates (1/4 and 2/7, respectively); one refractory child achieved remission with everolimus after sirolimus failure. At a median 5-year follow-up, endoscopic and histological remissions were reached in 54.5% (6/11) and 57.1% (4/7) of re-evaluated patients. CONCLUSIONS: PIL poses significant therapeutic challenges. Our findings show a loss of response to dietary management over time in a subset of patients, requiring tailored second-line pharmacological interventions whose management currently relies on limited clinical experiences in refractory cases.

Authors

Institutions

Publication Details

Journal
Journal of Pediatric Gastroenterology and Nutrition
Published
2026-11-18
DOI
https://doi.org/10.1002/jpn3.70690
Primary Topic
Lymphatic Disorders and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Long‐term outcome of dietary therapy in primary intestinal lymphangiectasia: Are we achieving sustained remission? A national retrospective study

Paolo Lionetti, Sara Renzo, Claudio Romano, Antonella Diamanti et al.
2 links
Journal of Pediatric Gastroenterology and Nutrition
Lymphatic Disorders and Treatments
article

Long‐term outcome of dietary therapy in primary intestinal lymphangiectasia: Are we achieving sustained remission? A national retrospective study

Paolo Lionetti, Sara Renzo, Claudio Romano, Antonella Diamanti, Sara Naldini, Lorenzo Norsa, Marco Crocco, Luca Scarallo, Irene Dalpiaz, Andrea Chiaro, Flavio Labriola
article en

Abstract

OBJECTIVES: Primary intestinal lymphangiectasia (PIL) is a rare congenital malformation causing protein-losing enteropathy. Given limited data on long-term dietary outcomes, this study describes clinical features, dietary response durability, and second-line therapies in an Italian pediatric cohort. METHODS: This multicenter retrospective study (2012-2025) analyzed children with PIL. Complete clinical remission required symptom resolution, normalized serum albumin, and intravenous albumin independence. Endoscopic and histological remissions were defined as the absence of macroscopic alterations and lymphatic vessel dilatation, respectively. RESULTS: Eighteen patients were included (median onset/diagnosis: 9 and 16 months, respectively). Key symptoms were ascites (82.4%), peripheral edema (76.5%), and lymphedema (64.7%); 94.1% showed profound hypoalbuminemia, hypoproteinemia, and hypogammaglobulinemia. Endoscopy revealed "snowflake" mucosa in 86.7%. Although all started a low-fat, high-protein medium-chain triglycerides diet, only 27.7% (5/18) achieved sustained complete remission on diet alone. Due to dietary failure, 55.6% (10/18) required second-line treatments (octreotide, sirolimus), with limited remission rates (1/4 and 2/7, respectively); one refractory child achieved remission with everolimus after sirolimus failure. At a median 5-year follow-up, endoscopic and histological remissions were reached in 54.5% (6/11) and 57.1% (4/7) of re-evaluated patients. CONCLUSIONS: PIL poses significant therapeutic challenges. Our findings show a loss of response to dietary management over time in a subset of patients, requiring tailored second-line pharmacological interventions whose management currently relies on limited clinical experiences in refractory cases.

Journal of Pediatric Gastroenterology and Nutrition
University of Messina (IT), University of Milan (IT), Istituto Giannina Gaslini (IT), Ospedale Maggiore Carlo Alberto Pizzardi (IT), Ospedale Papa Giovanni XXIII (IT), Meyer Children's Hospital (IT), Bambino Gesù Children's Hospital (IT), Ospedale dei Bambini Vittore Buzzi (IT), University of Florence (IT)
Good health and well-being
Lymphatic Disorders and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon